MGX Earnings Date & History
Metagenomi Therapeutics Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 4:08 PM ET
Metagenomi Therapeutics Inc
Biotechnology
- Next earnings date
- Wednesday, August 19, 2026
- Reporting session
- Time TBD
- EPS estimate
- $-0.58
- Revenue estimate
- $3.0M
MGX earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Monday, May 11, 2026 | Q1 2026 | $-0.53 | $-0.61 | -14.7% | $1.2M |
| Thursday, March 5, 2026 | Q4 2025 | $-0.61 | $-0.60 | +1.9% | $3.9M |
| Tuesday, November 11, 2025 | Q3 2025 | $-0.59 | $-0.55 | +6.7% | $8.7M |
| Tuesday, August 12, 2025 | Q2 2025 | $-0.63 | $-0.54 | +13.9% | $8.5M |
What the market is watching in MGX's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next MGX earnings date?
- Metagenomi Therapeutics Inc is scheduled to report on Wednesday, August 19, 2026 (Time TBD). Dates can change until the company confirms them.
- Does MGX report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for MGX?
- Consensus EPS for the upcoming quarter is $-0.58, on revenue of $3.0M.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
MGX earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.